At the time of writing, ATAI Life Sciences N.V [ATAI] stock is trading at $5.86, down -1.68%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ATAI shares have gain 3.90% over the last week, with a monthly amount glided 10.78%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ATAI Life Sciences N.V [NASDAQ: ATAI] stock has seen the most recent analyst activity on October 13, 2025, when Needham initiated its Buy rating and assigned the stock a price target of $12. Previously, Oppenheimer started tracking the stock with Outperform rating on July 29, 2025, and set its price target to $14. On November 18, 2024, H.C. Wainwright reiterated its Buy rating and revised its price target to $10 on the stock. Maxim Group upgraded its rating to a Buy but stick to its price target of $6 on April 03, 2024. Loop Capital initiated its recommendation with a Buy and recommended $18 as its price target on November 01, 2022. Maxim Group started tracking with a Buy rating for this stock on November 30, 2021, and assigned it a price target of $25. In a note dated November 11, 2021, ROTH Capital initiated a Buy rating and provided a target price of $32 on this stock.
For the past year, the stock price of ATAI Life Sciences N.V fluctuated between $1.04 and $6.75. Currently, Wall Street analysts expect the stock to reach $10.33 within the next 12 months. ATAI Life Sciences N.V [NASDAQ: ATAI] shares were valued at $5.86 at the most recent close of the market. An investor can expect a potential return of 76.28% based on the average ATAI price forecast.
Analyzing the ATAI fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -42.66%, Pretax Profit Margin comes in at -51.8%, and Net Profit Margin reading is -51.71%. To continue investigating profitability, this company’s Return on Assets is posted at -0.63, Equity is -0.86 and Total Capital is -0.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.72 points at the first support level, and at 5.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.00, and for the 2nd resistance point, it is at 6.14.
Ratios To Look Out For
It is important to note that ATAI Life Sciences N.V [NASDAQ:ATAI] has a current ratio of 4.02. Further, the Quick Ratio stands at 4.02, while the Cash Ratio is 2.42. Considering the valuation of this stock, the price to sales ratio is 4635.85, the price to book ratio is 8.65.
Transactions by insiders
Recent insider trading involved Apeiron Investment Group Ltd., 10% Owner, that happened on Aug 14 ’25 when 8.68 million shares were purchased. Officer, SAHIL KIRPEKAR completed a deal on Jul 02 ’25 to buy 83332.0 shares. Meanwhile, Officer SAHIL KIRPEKAR bought 0.11 million shares on Jul 01 ’25.
